DarioHealth Corp. (NASDAQ:DRIO – Get Rating) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.02 and traded as low as $4.08. DarioHealth shares last traded at $4.22, with a volume of 154,609 shares.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the company. Aegis decreased their price target on DarioHealth from $20.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, August 18th. Cowen decreased their price target on DarioHealth from $18.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, August 16th. Cowen decreased their price target on DarioHealth from $18.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, August 16th. Finally, Alliance Global Partners upgraded DarioHealth from a “neutral” rating to a “buy” rating and set a $8.75 price target for the company in a report on Friday, May 13th.
DarioHealth Stock Performance
The company has a market capitalization of $96.97 million, a PE ratio of -1.13 and a beta of 1.27. The company has a debt-to-equity ratio of 0.23, a quick ratio of 5.71 and a current ratio of 6.35. The company has a 50 day moving average price of $5.75 and a 200 day moving average price of $6.02.
Institutional Investors Weigh In On DarioHealth
Several institutional investors and hedge funds have recently made changes to their positions in DRIO. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of DarioHealth during the 1st quarter valued at approximately $9,357,000. Phoenix Holdings Ltd. increased its position in DarioHealth by 391.3% in the first quarter. Phoenix Holdings Ltd. now owns 1,341,027 shares of the company’s stock worth $7,832,000 after buying an additional 1,068,092 shares during the period. Millennium Management LLC increased its position in DarioHealth by 729.9% in the second quarter. Millennium Management LLC now owns 488,772 shares of the company’s stock worth $3,001,000 after buying an additional 429,880 shares during the period. MAI Capital Management acquired a new stake in DarioHealth in the second quarter worth $2,140,000. Finally, Nantahala Capital Management LLC increased its position in DarioHealth by 21.6% in the first quarter. Nantahala Capital Management LLC now owns 1,716,007 shares of the company’s stock worth $10,021,000 after buying an additional 304,326 shares during the period. 46.50% of the stock is owned by institutional investors and hedge funds.
DarioHealth Company Profile
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems.
- Get a free copy of the StockNews.com research report on DarioHealth (DRIO)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- Are These Green Energy Companies Right For Your Portfolio?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.